



The Brazilian Journal of INFECTIOUS DISEASES

www.elsevier.com/locate/bjid



Case report

Rare severe mycotic infections in children receiving empirical caspofungin treatment for febrile neutropenia



Deniz Yılmaz Karapınar^{a,*}, Nihal Karadaş^a, Zühal Önder Siviş^a, Pinar Yazıcı^b, Muhterem Duyu^b, Dilek Metin^c, Bülent Karapınar^b, Yeşim Aydınok^a

^a Children's Hospital, Department of Pediatric Hematology, Ege University Faculty of Medicine, Bornova-İzmir, Turkey

^b Children's Hospital, Department of Pediatric Intensive Care, Ege University Faculty of Medicine, Bornova-İzmir, Turkey

^c Medical Microbiology, Ege University Faculty of Medicine, Bornova-İzmir, Turkey

ARTICLE INFO

Article history:

Received 30 March 2015

Accepted 12 June 2015

Available online 11 August 2015

Keywords:

Geotrichum capitatum

Trichosporon asahii

Invasive fungal infection

Febrile neutropenia

ABSTRACT

Empirical antifungal therapy is most often given to patients with leukemia. However breakthrough fungal infections under antifungal therapy are not uncommon. Four children, with hematologic malignant disease developed mycotic breakthrough infections while on empirical caspofungin treatment for a median of 14 (range 11–19) days. *Trichosporon asahii* was detected in the blood culture of two patients and *Geotrichum capitatum* in the other two (one patient also had positive cerebrospinal fluid culture). Because the patients' clinical situation worsened, voriconazole was empirically added for two patients three and five days before the agent was detected. The first sterile blood culture was obtained 3–7 days of voriconazole treatment. All patients reached clear cultures but one patient died. One patient with central nervous system infection with *G. capitatum* had severe neurological sequelae. Very severe fungal infections can occur during empirical caspofungin therapy. Therefore, patients should be followed closely.

© 2015 Elsevier Editora Ltda. All rights reserved.

Introduction

Invasive fungal infections (IFIs) have significant impact on leukemia patients' survival. Although antifungal drugs are empirically given to most of the patients, breakthrough fungal infections are not uncommon.^{1–5}

Trichosporon infections are an increasingly common complication of neutropenia and other conditions associated with severe immunocompromise. The outcome of disseminated *Trichosporon* infection is most often poor, and the fatality rate is over 70%.^{3,6–9} Recently the genus *Trichosporon* has been taxonomically revised. Generally, two species have been associated

* Corresponding author at: 236 Sok. No: 1 Kat: 7 D: 21, Baris Apt. 35040, Bayrakli-Izmir, Turkey.

E-mail address: dyilmazk@yahoo.com (D. Yılmaz Karapınar).

<http://dx.doi.org/10.1016/j.bjid.2015.06.008>

1413-8670/© 2015 Elsevier Editora Ltda. All rights reserved.

with IFIs in humans: *Trichosporon beigeli* and *Trichosporon capitatum*. *T. capitatum* has now been reclassified as *Geotrichum capitatum* or *Blastoschizomyces capitatus*. *T. beigeli* now corresponds to six different species. Invasive *Trichosporon* infections are due to *T. asahii* in most cases.^{6,7}

The increased use of echinocandins leads to significant selective pressure, which favors opportunistic fungi, that are resistant to these agents. Disseminated trichosporonosis has been reported in immunocompromised patients under echinocandin therapy.^{3,4,7-14} Breakthrough trichosporonosis and *G. capitatum* infections occurred in four children on empirical caspofungin therapy.

Case reports

Case 1

A 16-year-old girl with acquired very severe aplastic anemia (vSAA) received immunosuppressive therapy (IST) consisting of rabbit anti-thymocyte globuline (ATG), cyclosporine A, granulocyte colony stimulating factor (GCSF), and prednisolone after replacement of central venous catheter (CVC). She had no hematological response to IST. Six months after diagnosis of vSAA and 44 days after initiation of IST, the patient was still on regular platelet and erythrocyte transfusion, had very severe neutropenia, and developed febrile neutropenia (FN). On 6th day of FN caspofungin was initiated as empirical antifungal therapy. She developed maculopapular rash on 11th day of caspofungin treatment. Her clinical condition worsened. The patient developed hepatosplenomegaly (HSM) and severe respiratory distress. She was admitted to the pediatric intensive care unit (PICU), and required mechanical ventilation (MV). Blood cultures taken 15 days after initiation of caspofungin revealed yeast, later identified as *T. asahii*. Table 1 shows the minimal inhibitory concentration (MIC) of antifungals. Voriconazole (VCZ) was started. Although blood cultures were negative seven days after initiation of VCZ, the patient clinical condition did not improve. Fever, HSM, respiratory failure, and pancytopenia persisted. She developed renal failure and expired 13 days after clearing blood culture.

Case 2

A 5-year-old girl with pre-B cell acute lymphoblastic leukemia (ALL) was included in the standard risk (SR) arm of ALL IC-BFM 2002 treatment protocol. A CVC was inserted. On 42nd day of treatment (day 0), she developed FN (ANC was 12 mm^{-3}) and empirical caspofungin was started on day 5 thereafter. She presented diarrhea and feeding intolerance. Leukemia treatment was discontinued on day 21 (63rd day of induction therapy). Disseminated maculopapular lesions appeared and she developed sepsis. VCZ (4 mg/kg every 12 h) was added to treatment empirically on day 26 and three days later she developed severe respiratory distress. CVC was removed. The patient was transferred to PICU, requiring intubation and MV. Cultures of three blood samples obtained 19 days after initiation of caspofungin treatment and three days before starting VCZ yielded yeasts, later identified as *T. asahii*. The agent was sensitive to VCZ (Table 1). Although all blood cultures became

negative after four days of VCZ therapy, she developed secondary hemophagocytosis (HLH) and was treated according to HLH 2004 protocol for two weeks. After resolution of clinical and laboratory findings related to secondary HLH, she continued to receive ALL IC-BFM 2002 chemotherapy protocol. Secondary antifungal prophylaxis was administered with VCZ for six months and she completed the chemotherapy protocol without reactivation of *T. asahii*.

Case 3

A 2.5-year-old boy with pre-B cell ALL was included in HR arm of ALL IC-BFM 2002 treatment protocol. A port catheter was inserted. On 22nd day of treatment (day 0), he developed FN (ANC was 12 mm^{-3}). Empirical caspofungin was started on day 4. He could not achieve hematologic remission by day 15 (33rd day of treatment protocol) and on day 17, VCZ was added as a second antifungal agent due to worsening clinical condition. Serum galactomannan test was found to be positive. Blood samples for culture were taken on day 18 (14th day of Caspofungin treatment and 1st day of voriconazole treatment) yielded yeasts, later identified as *G. capitatum*. On day 19, caspofungin was stopped and liposomal amphotericin B (LiAmB) was started at the dose of 5 mg/kg, then the dose was increased up to 10 mg/kg/day. Blood cultures were negative on day 23, eight days after VCZ initiation and four days of LiAmB. CVC was removed and culture of the catheter tip yielded the same fungi. Antifungal therapy was continued with combined antifungals for three months without reactivation of IFI.

Case 4

A 2.5-year-old girl with pre-B cell ALL was included in HR arm of ALL IC-BFM 2002 treatment protocol after insertion of CVC. She had central nervous system involvement. On the 4th day (day 0) of treatment, she developed FN (ANC was 104 mm^{-3}). Empirical caspofungin was started on day 8. Fever disappeared 12 days thereafter. A port catheter was inserted on day 15. While she was still on caspofungin treatment she again developed febrile neutropenia on day 17. On day 21, abdominal computerized tomography showed multiple spleen and kidney hypodense nodular lesions with less than 1 cm diameter. On day 25 she developed severe agitation, and cranial magnetic resonance imaging (MRI) showed multiple diffuse cortical and subcortical lesions. On day 29 (33rd day of treatment), bone marrow aspiration revealed hematological remission, and intrathecal treatment was given after cerebrospinal fluid (CSF) sample was taken according to the protocol. Two days later, on day 31, she developed status epilepticus. She was then transferred to PICU and required MV. Serum galactomannan antigen test was found to be weak positive. Empirical VCZ (8 mg/kg/day) was added. On day 32, CSF culture yielded yeasts, later identified as *G. capitatum*. Antifungal susceptibility is shown in Table 1. Caspofungin was stopped and LiAmB was started at the dose of 5 mg/kg/day. Catheter tip, peripheral blood, and urine cultures yielded *G. capitatum*. Port catheter was removed. After four days of LiAmB and five days of VCZ all blood cultures were negative. However, cranial MRI showed progressive encephalitis on day 40. CSF reservoir was inserted and CSF samples from

Table 1 – Minimum inhibitory concentration ($\mu\text{g/mL}$) of antifungal drugs displayed against isolate.

Patient no.	Isolate (isolation site)	Amp B	Fluconazole	Itraconazole	Voriconazole	Posaconazole	Caspofungin	Amidalfungin
1	<i>T. asahii</i> (Blood)	1.5	3	0.032	0.094		>32	32
2	<i>G. capitatum</i> (Blood, CSF, urine)	0.032	4	0.064	0.064	0.125	>32	32
3	<i>G. capitatum</i> (Blood)	0.032	4	0.50	0.125		>32	6
4	<i>T. asahii</i> (Blood)	0.008	0.023	0.25	0.023		>32	32
6	<i>G. capitatum</i> (Blood)	0.75	3	0.9	0.125		>32	12

the reservoir yielded *G. capitatum*. Intrathecal amphotericin B at the dose of 0.25 mg/day was given. The first sterile CSF culture was achieved after 16 days of intravenous VCZ, 15 days of LiAmB, and four days of intrathecal amphotericin B. Despite antibiotic and antifungal therapies, fever persisted. Cranial MRI showed progressive encephalitis, external ventricular drainage was inserted and intrathecal AmB was given for 21 days. She weaned from MV 78 days thereafter. She continued to receive combined antifungal therapy for 267 days but developed severe neurological sequelae.

Discussion

IFI is a significant cause of morbidity and mortality among patients with hematologic malignancies. Empirical antifungal therapy is highly recommended after four days of FN in this population. Caspofungin and amphotericin B are the suggested antifungal agents for empirical therapy.¹⁵

Invasive infections caused by *Trichosporon* species are rare but potentially fatal complications of the immunosuppression associated with treatment of cancer.^{3,7} Among *Trichosporon* species, *G. capitatum* has emerged as a rare fungal pathogen in recent years, particularly in severely immunocompromised hosts. IFI caused by this agent is often characterized by a multiorgan involvement with a fatal course despite antifungal therapy.¹⁶⁻¹⁹ The incidence of *G. capitatum* infection among patients with leukemia was found to be 0.5% with a crude mortality rate of 55%. Several studies collecting cases of *G. capitatum* infections in hematological patients have showed a 30-day attributable mortality ranging from 40% to 75%.

Caspofungin has a good fungistatic and fungicidal activity against a variety of yeasts, but does not show activity against *G. capitatum* and the other fungi of *Trichosporon* species.^{2-5,17}

The presented four patients with hematologic malignant disease developed severe fungal breakthrough infections with rare causative agents. All of the patients had a CVC, very severe neutropenia, and were initially treated with broad-spectrum antibiotics. Since fever and severe neutropenia persisted in all patients, empirical changes in antibiotic combinations were implemented despite no agent being isolated in the cultures. At a median of five days (range 4–8 days) of FN, caspofungin was started in all these patients, who had fever and hepatosplenomegaly. Cutaneous maculopapular rash was seen in two patients. One had status epilepticus and multiple cerebral abscesses at presentation of mycotic infection. Three of these

patients required intubation and MV, and were admitted at the PICU.

Because the patients' clinical situation worsened, in two patients VCZ was added to antifungal therapy empirically one and three days before the agent was detected.

Echinocandins alone have little to no activity against *Trichosporon* spp. and are not recommended for trichosporonosis treatment.²⁻⁵ In the literature almost all IFIs caused by *T. asahii* or *G. capitatum* occurred as breakthrough infection in patients who received antifungal therapy, especially echinocandins for at least five to seven days.⁸⁻¹⁰

Fluconazole was used as the initial therapy in 85% of 19 patients with invasive trichosporonosis documented in a single medical center in Taiwan, and the mortality rate was 42%.⁹ Suzuki et al.¹⁰ recently evaluated the clinical and therapeutic aspects of 33 cases of *Trichosporon* fungemia documented in patients with hematological malignancies. The authors clearly demonstrated that survival was longer for patients treated with an azole than for those treated with other drugs. Triazoles seem to have better *in vitro* and *in vivo* antifungal activity against *Trichosporon* spp. than amphotericin B. VCZ also has excellent *in vitro* activity against *Trichosporon* strains and may be useful for treating patients with trichosporonosis.^{3,6}

In conclusion, disseminated trichosporonosis and *G. capitatum* infections have been increasingly reported worldwide. Treatment with echinocandins should be accepted as a risk factor in immunosuppressed patients, especially in institutions where the infection had been detected before. Prognosis is limited, and antifungal regimens containing triazoles appear to be the best therapeutic approach.

Conflicts of interest

The authors declare no conflicts of interest.

REFERENCES

- Lafaurie M, Lapalu J, Raffoux E, et al. High rate breakthrough invasive aspergillosis among patients receiving caspofungin for persistent fever and neutropenia. *Clin Microbiol Infect.* 2010;16:1191-6.
- Walsh TJ, Groll A, Hiemenz J, Fleming R, Roilides E, Anaissie E. Infections due to emerging and uncommon medically

- important fungal pathogens. *Clin Microbiol Infect.* 2004;10:44-6.
3. Arendrup MC, Boekhout T, Akova M, et al. ESCMID and ECMM joint clinical guidelines for the diagnosis and management of rare invasive yeast infections. *Clin Microbiol Infect.* 2014;20:76-98.
 4. Chan TS, Gill H, Hwang YY, et al. Breakthrough invasive fungal diseases during echinocandin treatment in high-risk hospitalized hematologic patients. *Ann Hematol.* 2014;93:493-8.
 5. Caira M, Trecarichi EM, Tumbarello M, Leone G, Pagano L. Uncommon yeast infections in hematological patients: from diagnosis to treatment. *Expert Rev Anti Infect Ther.* 2011;9:1067-75.
 6. Colombo AL, Padovan ACB, Chaves GM. Current knowledge of *Trichosporon* spp. and trichosporonosis. *Clin Microbiol Rev.* 2011;24:682-700.
 7. Meyer MH, Letscher-Bru V, Waller J, Lutz P, Marcellin L, Herbrecht R. Chronic disseminated *Trichosporon asahii* infection in a leukemic child. *Clin Infect Dis.* 2002;35:e22-5.
 8. Kontoyiannis DP, Torres HA, Chagua M, et al. Trichosporonosis in a tertiary care cancer center: risk factors, changing spectrum and determinants of outcome. *Scand J Infect Dis.* 2004;36:564-9.
 9. Ruan SY, Chien JY, Hsueh PR. Invasive trichosporonosis caused by *Trichosporon asahii* and other unusual *Trichosporon* species at a medical center in Taiwan. *Clin Infect Dis.* 2009;49:11-7.
 10. Suzuki K, Nakase K, Kyo T, et al. Fatal *Trichosporon fungemia* in patients with hematologic malignancies. *Eur J Haematol.* 2010;84:441-7.
 11. Liao Y, Harmann T, Zheng T, Yang RY, Ao JH, Wang WL. Breakthrough trichosporonosis in patients receiving echinocandins: case report and literature review. *Chin Med J.* 2012;125:2632-5.
 12. Sun HY, Singh N. Characterisation of breakthrough invasive mycoses in echinocandin recipients: an evidence-based review. *Int J Antimicrob Agents.* 2010;35:211-8.
 13. Bayramoglu G, Sonmez M, Tosun I, Aydin K, Aydin F. Breakthrough *Trichosporon asahii* fungemia in neutropenic patient with acute leukemia while receiving caspofungin. *Infection.* 2008;36:68-70.
 14. Ozkaya-Parlakay A, Karadag-Oncel E, Cengiz AB, et al. *Trichosporon asahii* sepsis in a patient with pediatric malignancy. *J Microbiol Immunol Infect.* 2013;13, 1684-1182.
 15. Maertens JA, Madero L, Reilly AF, et al. A randomized, double blind, multicenter study of caspofungin versus liposomal amphotericin B for empiric antifungal therapy in pediatric patients with persistent fever and neutropenia. *Pediatr Infect Dis.* 2010;29:415-20.
 16. Ikuta K, Torimoto Y, Yamamoto M, et al. Successful treatment of systemic *Geotrichum capitatum* infection by liposomal amphotericin B, itraconazole, and voriconazole in Japanese man. *Intern Med.* 2010;49:2499-503.
 17. Fianchi L, Montini L, Caira M, et al. Combined voriconazole plus caspofungin therapy for the treatment of probable *geotrichum* pneumonia in a leukemia patient. *Infection.* 2008;36:65-7.
 18. Etienne A, Datry A, Gaspar N, et al. Successful treatment of disseminated *Geotrichum capitatum* infection with a combination of caspofungin and voriconazole in an immunocompromised patient. *Mycoses.* 2008;51:270-2.
 19. Christakis G, Perlorentzou S, Aslanidou M, Megalakaki A, Veleglaki A. Fatal *Blastoschizomyces capitatus* sepsis in a neutropenic patient with acute myeloid leukemia: first documented case from Greece. *Mycoses.* 2004;48:216-20.